Symbols / EDIT Stock $2.78 -1.42% Editas Medicine, Inc.

Healthcare • Biotechnology • United States • NMS
EDIT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Gilmore O'Neill M.D.
Exch · Country NMS · United States
Market Cap 426.62M
Enterprise Value 165.83M
Income -108.95M
Sales 38.69M
FCF (ttm) -73.82M
Book/sh 0.04
Cash/sh 1.26
Employees 87
Insider 10d —
IPO Feb 03, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.97
PEG —
P/S 11.03
P/B 61.78
P/C —
EV/EBITDA -1.95
EV/Sales 4.29
Quick Ratio 3.17
Current Ratio 3.22
Debt/Eq 392.40
LT Debt/Eq —
EPS (ttm) -1.14
EPS next Y -0.94
EPS Growth —
Revenue Growth -39.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -26.95%
ROE -3.26%
ROIC —
Gross Margin -109.24%
Oper. Margin -8.83%
Profit Margin -281.59%
Shs Outstand 153.46M
Shs Float 97.73M
Insider Own 0.18%
Instit Own 37.31%
Short Float 9.79%
Short Ratio 7.43
Short Interest 9.56M
52W High 4.54
vs 52W High -38.73%
52W Low 1.66
vs 52W Low 67.47%
Beta 2.14
Impl. Vol. 12.50%
Rel Volume 1.54
Avg Volume 2.06M
Volume 3.19M
Target (mean) $5.78
Tgt Median $5.00
Tgt Low $1.00
Tgt High $15.00
# Analysts 9
Recom Buy
Prev Close $2.82
Price $2.78
Change -1.42%
About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.78
Mean price target
2. Current target
$2.78
Latest analyst target
3. DCF / Fair value
$-8.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.78
Low
$1.00
High
$15.00
Mean
$5.78

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-05 main Chardan Capital Buy → Buy $4
2026-03-10 up Jones Trading Hold → Buy $8
2026-03-09 main Chardan Capital Buy → Buy $4
2025-09-05 reit HC Wainwright & Co. Buy → Buy $5
2025-09-03 main Wells Fargo Equal-Weight → Equal-Weight $4
2025-08-15 main HC Wainwright & Co. Buy → Buy $5
2025-08-13 main Baird Outperform → Outperform $6
2025-05-13 main Baird Outperform → Outperform $4
2025-04-28 init HC Wainwright & Co. — → Buy $3
2024-12-16 main Evercore ISI Group Outperform → Outperform $5
2024-12-16 down JP Morgan Neutral → Underweight —
2024-12-13 main RBC Capital Sector Perform → Sector Perform $4
2024-12-13 main Barclays Equal-Weight → Equal-Weight $3
2024-12-13 down Chardan Capital Buy → Neutral —
2024-12-13 main Baird Outperform → Outperform $8
2024-12-13 down Stifel Buy → Hold $3
2024-12-11 down Wells Fargo Overweight → Equal-Weight $4
2024-11-05 main Chardan Capital Buy → Buy $12
2024-11-05 main RBC Capital Sector Perform → Sector Perform $5
2024-11-05 main Stifel Buy → Buy $11
News
RSS: Latest EDIT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-03 O NEILL GILMORE NEIL Chief Executive Officer — 5,394 $2.02 $10,894
2026-03-03 BURKLY LINDA Officer — 749 $2.02 $1,513
2026-03-03 PARISON AMY Chief Financial Officer — 474 $2.02 $957
2025-12-03 O NEILL GILMORE NEIL Chief Executive Officer — 5,603 $2.15 $12,064
2025-12-03 BURKLY LINDA Officer — 713 $2.15 $1,535
2025-12-03 PARISON AMY Chief Financial Officer — 461 $2.15 $993
2025-09-03 O NEILL GILMORE NEIL Chief Executive Officer — 5,592 $2.60 $14,517
2025-09-03 BURKLY LINDA Officer — 710 $2.60 $1,843
2025-09-03 PARISON AMY Chief Financial Officer — 458 $2.60 $1,189
2025-08-07 PARISON AMY Chief Financial Officer — 679 $2.58 $1,752
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
40.52
+25.39%
32.31
-58.64%
78.12
+296.32%
19.71
Operating Revenue
40.52
+25.39%
32.31
-58.64%
78.12
+296.32%
19.71
Operating Expense
139.86
-48.44%
271.23
+9.68%
247.30
+0.67%
245.66
Research And Development
89.95
-54.85%
199.25
+12.16%
177.65
+1.54%
174.96
Selling General And Administration
49.90
-30.68%
71.99
+3.35%
69.65
-1.49%
70.70
General And Administrative Expense
49.90
-30.68%
71.99
+3.35%
69.65
-1.49%
70.70
Salaries And Wages
19.24
-42.63%
33.54
+24.57%
26.93
-21.25%
34.19
Other Gand A
30.66
-20.25%
38.45
-10.02%
42.73
-39.57%
70.70
Total Expenses
139.86
-48.44%
271.23
+9.68%
247.30
+0.67%
245.66
Operating Income
-99.34
+58.42%
-238.92
-41.22%
-169.18
+25.12%
-225.95
Total Operating Income As Reported
-160.01
+36.29%
-251.15
-48.45%
-169.18
+25.12%
-225.95
EBITDA
-148.61
+35.13%
-229.09
-40.45%
-163.12
+25.73%
-219.61
Normalized EBITDA
-87.94
+59.45%
-216.86
-32.95%
-163.12
+25.73%
-219.61
Reconciled Depreciation
5.28
-9.16%
5.81
-4.21%
6.06
-4.31%
6.34
EBIT
-153.89
+34.49%
-234.90
-38.85%
-169.18
+25.12%
-225.95
Total Unusual Items
-60.67
-396.03%
-12.23
0.00
0.00
Total Unusual Items Excluding Goodwill
-60.67
-396.03%
-12.23
0.00
0.00
Special Income Charges
-60.67
-396.03%
-12.23
0.00
0.00
Restructuring And Mergern Acquisition
60.67
+396.03%
12.23
0.00
0.00
Net Income
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Pretax Income
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Net Non Operating Interest Income Expense
2.14
-84.79%
14.06
-19.95%
17.57
+218.34%
5.52
Interest Expense Non Operating
6.17
+181.78%
2.19
—
—
Net Interest Income
2.14
-84.79%
14.06
-19.95%
17.57
+218.34%
5.52
Interest Expense
6.17
+181.78%
2.19
—
—
Interest Income Non Operating
8.31
-48.87%
16.25
-7.48%
17.57
+218.34%
5.52
Interest Income
8.31
-48.87%
16.25
-7.48%
17.57
+218.34%
5.52
Other Income Expense
-62.86
-413.80%
-12.23
-662.78%
-1.60
-224.05%
1.29
Other Non Operating Income Expenses
-2.19
-72866.67%
-0.00
+99.81%
-1.60
-224.05%
1.29
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Net Income From Continuing Operation Net Minority Interest
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Net Income From Continuing And Discontinued Operation
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Net Income Continuous Operations
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Normalized Income
-99.39
+55.80%
-224.86
-46.76%
-153.22
+30.49%
-220.43
Net Income Common Stockholders
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Diluted EPS
—
-2.88
-42.57%
-2.02
+37.07%
-3.21
Basic EPS
—
-2.88
-42.57%
-2.02
+37.07%
-3.21
Basic Average Shares
—
82.34
+8.39%
75.97
+10.63%
68.66
Diluted Average Shares
—
82.34
+8.39%
75.97
+10.63%
68.66
Diluted NI Availto Com Stockholders
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Line Item Trend 2023-12-31
Total Assets
499.15
Current Assets
340.83
Cash Cash Equivalents And Short Term Investments
323.11
Cash And Cash Equivalents
123.65
Cash Equivalents
123.65
Other Short Term Investments
199.46
Receivables
10.19
Accounts Receivable
10.19
Prepaid Assets
—
Other Current Assets
7.53
Total Non Current Assets
158.32
Net PPE
45.71
Gross PPE
71.97
Accumulated Depreciation
-26.26
Properties
0.00
Machinery Furniture Equipment
1.54
Construction In Progress
2.06
Other Properties
58.72
Leases
9.65
Investments And Advances
104.02
Other Non Current Assets
8.59
Total Liabilities Net Minority Interest
150.06
Current Liabilities
63.22
Payables And Accrued Expenses
31.55
Payables
8.27
Accounts Payable
8.27
Current Accrued Expenses
23.28
Pensionand Other Post Retirement Benefit Plans Current
11.28
Current Debt And Capital Lease Obligation
12.16
Current Capital Lease Obligation
12.16
Current Deferred Liabilities
8.22
Current Deferred Revenue
8.22
Total Non Current Liabilities Net Minority Interest
86.84
Long Term Debt And Capital Lease Obligation
24.37
Long Term Capital Lease Obligation
24.37
Non Current Deferred Liabilities
60.67
Non Current Deferred Revenue
60.67
Other Non Current Liabilities
1.80
Stockholders Equity
349.10
Common Stock Equity
349.10
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
81.77
Ordinary Shares Number
81.77
Treasury Shares Number
0.00
Additional Paid In Capital
1,580.24
Retained Earnings
-1,231.35
Gains Losses Not Affecting Retained Earnings
0.20
Other Equity Adjustments
0.20
Total Equity Gross Minority Interest
349.10
Total Capitalization
349.10
Working Capital
277.61
Invested Capital
349.10
Total Debt
36.54
Capital Lease Obligations
36.54
Net Tangible Assets
349.10
Tangible Book Value
349.10
Available For Sale Securities
104.02
Investmentin Financial Assets
104.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-165.24
+21.42%
-210.28
-59.09%
-132.18
+25.47%
-177.35
Cash Flow From Continuing Operating Activities
-165.24
+21.42%
-210.28
-59.09%
-132.18
+25.47%
-177.35
Net Income From Continuing Operations
-160.06
+32.49%
-237.09
-54.74%
-153.22
+30.49%
-220.43
Depreciation Amortization Depletion
5.28
-9.16%
5.81
-4.21%
6.06
-4.31%
6.34
Depreciation
5.28
-9.16%
5.81
-4.21%
6.06
-4.31%
6.34
Depreciation And Amortization
5.28
-9.16%
5.81
-4.21%
6.06
-4.31%
6.34
Other Non Cash Items
5.72
+222.37%
1.77
+11.22%
1.60
+320.44%
-0.72
Stock Based Compensation
10.00
-53.31%
21.42
+8.18%
19.80
-32.42%
29.29
Asset Impairment Charge
3.76
0.00
—
—
Operating Gains Losses
2.19
+1371.81%
0.15
—
—
Unrealized Gain Loss On Investment Securities
—
—
—
0.00
Gain Loss On Sale Of PPE
2.19
+1371.81%
0.15
0.00
0.00
Change In Working Capital
-31.23
-1005.19%
3.45
+316.44%
-1.59
-119.50%
8.18
Change In Receivables
1.09
+117.93%
-6.08
-20.57%
-5.04
-3.36%
-4.88
Changes In Account Receivables
1.09
+117.93%
-6.08
-20.57%
-5.04
-3.36%
-4.88
Change In Prepaid Assets
1.06
-75.84%
4.40
+2331.47%
-0.20
-43.80%
-0.14
Change In Payables And Accrued Expense
-16.07
-272.13%
9.34
+256.10%
2.62
-82.37%
14.87
Change In Accrued Expense
-13.18
-213.43%
11.62
+182.52%
4.11
-60.84%
10.51
Change In Payable
-2.89
-26.33%
-2.29
-53.22%
-1.49
-134.16%
4.37
Change In Account Payable
-2.89
-26.33%
-2.29
-53.22%
-1.49
-134.16%
4.37
Change In Other Working Capital
-18.04
-113.21%
-8.46
—
-3.33
Change In Other Current Assets
12.62
+181.03%
4.49
-32.28%
6.63
+141.67%
-15.92
Change In Other Current Liabilities
-11.89
-5002.58%
-0.23
+95.85%
-5.61
-131.93%
17.57
Investing Cash Flow
138.67
-14.48%
162.15
+4445.91%
-3.73
-103.27%
114.07
Cash Flow From Continuing Investing Activities
138.67
-14.48%
162.15
+4445.91%
-3.73
-103.27%
114.07
Net PPE Purchase And Sale
-0.34
+96.17%
-8.83
-87.03%
-4.72
-15.10%
-4.10
Purchase Of PPE
-0.61
+93.12%
-8.83
-87.03%
-4.72
-14.59%
-4.12
Sale Of PPE
0.27
0.00
0.00
-100.00%
0.02
Capital Expenditure
-0.61
+93.12%
-8.83
-87.03%
-4.72
-14.59%
-4.12
Net Investment Purchase And Sale
139.01
-18.70%
170.97
+17204.86%
0.99
-99.16%
118.17
Purchase Of Investment
0.00
+100.00%
-86.22
+66.65%
-258.52
+17.98%
-315.19
Sale Of Investment
139.01
-45.95%
257.19
-0.89%
259.50
-40.12%
433.35
Financing Cash Flow
40.47
-27.77%
56.03
-52.54%
118.04
+9093.07%
1.28
Cash Flow From Continuing Financing Activities
40.47
-27.77%
56.03
-52.54%
118.04
+9093.07%
1.28
Net Common Stock Issuance
42.85
0.00
-100.00%
117.08
0.00
Proceeds From Stock Option Exercised
0.49
-36.91%
0.78
-18.44%
0.96
-25.23%
1.28
Net Other Financing Charges
-2.87
-105.20%
55.24
—
—
Changes In Cash
13.90
+76.16%
7.89
+144.15%
-17.87
+71.18%
-62.00
Beginning Cash Position
135.42
+6.19%
127.53
-12.29%
145.40
-29.89%
207.40
End Cash Position
149.31
+10.26%
135.42
+6.19%
127.53
-12.29%
145.40
Free Cash Flow
-165.85
+24.31%
-219.11
-60.05%
-136.90
+24.56%
-181.47
Amortization Of Securities
-0.90
+84.42%
-5.79
-20.07%
-4.82
-566.16%
-0.72
Common Stock Issuance
42.85
0.00
-100.00%
117.08
0.00
Issuance Of Capital Stock
42.85
0.00
-100.00%
117.08
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category